Galapagos appoints Raj Parekh as Chairman and Wilson Totten to Board of Directors
05 oct. 2004 02h08 HE
|
Crucell N.V.
MECHELEN, Belgium and LEIDEN, The Netherlands, Oct. 5, 2004 (PRIMEZONE) -- Galapagos Genomics NV announced that it has appointed Raj Parekh, Ph.D. as Chairman and Wilson Totten, M.D. to the company's...
Aviva / Delta Lloyd Acquires 5.09% Interest in Crucell
04 oct. 2004 06h05 HE
|
Crucell N.V.
LEIDEN, The Netherlands, Oct. 04, 2004 (PRIMEZONE) -- Dutch biotechnology company Crucell N.V. (Euronext:CRXL "(Nasdaq:CRXL) announced today that Aviva plc. / Delta Lloyd Levensverzekering N.V. has...
Crucell to Present at UBS Global Life Sciences Conference, New York, September 28
21 sept. 2004 08h08 HE
|
Crucell N.V.
LEIDEN, Netherlands, Sept. 21, 2004 (PRIMEZONE) -- Crucell N.V. (Euronext, Nasdaq: CRXL) has announced its President and CEO, Ronald Brus, will present at the UBS Global Life Sciences Conference to...
Crucell Grants IAVI Exclusive License to use AdVac Technology for AIDS Vaccine
14 sept. 2004 02h11 HE
|
Crucell N.V.
LEIDEN, The Netherlands, Sept. 14, 2004 (PRIMEZONE) -- Dutch biotechnology company Crucell and the International AIDS Vaccine Initiative (IAVI) have signed an exclusive license agreement to develop...
Crucell Announces PER.C6(R) Licensing Agreement with Vaxin for Adenoviral Vaccines
13 sept. 2004 08h14 HE
|
Crucell N.V.
LEIDEN, The Netherlands, Sept. 13, 2004 (PRIMEZONE) -- Dutch biotechnology company Crucell N.V. (Euronext, Nasdaq:CRXL) announced today that it has signed a non-exclusive PER.C6(R) technology license...
Crucell and DSM Announce PER.C6 Licensing Agreement with MorphoSys for Antibody Production
08 sept. 2004 02h10 HE
|
Crucell N.V.
LEIDEN and SITTARD, The Netherlands, Sept. 8, 2004 (PRIMEZONE) -- Dutch biotechnology company Crucell N.V. (Euronext:CRXL) (Nasdaq:CRXL) and allied contract manufacturer DSM Biologics announced today...
PER.C6(R)-produced HIV Vaccine Progresses Towards Next Phase
31 août 2004 10h16 HE
|
Crucell N.V.
LEIDEN, Netherlands, Aug. 31, 2004 (PRIMEZONE) -- At today's AIDS Vaccine 2004 conference in Lausanne, Switzerland, Merck & Co.'s Executive Director for vaccine research Dr. Robin Isaacs...
Crucell and Harvard Medical School Announce Promising Results for Novel Vaccine Technology (AdVac)
30 août 2004 08h07 HE
|
Crucell N.V.
LEIDEN, The Netherlands, Aug. 30, 2004 (PRIMEZONE) -- Dutch biotechnology company Crucell N.V. (Euronext:CRXL) (Nasdaq:CRXL) and Harvard Medical School today announced results of a joint study...
Crucell Announces PER.C6 Licensing Agreement with Wyeth Pharmaceuticals
25 août 2004 02h09 HE
|
Crucell N.V.
LEIDEN, The Netherlands, Aug. 25, 2004 (PRIMEZONE) -- Dutch biotechnology company Crucell N.V. (Euronext:CRXL) (Nasdaq:CRXL) announced today that it has signed a PER.C6(R) research license agreement...
Crucell and DSM Announce PER.C6 Licensing Agreement with Synergenics and Synco Bio Partners Investments for Production of Monoclonal Antibodies
20 août 2004 02h14 HE
|
Crucell N.V.
LEIDEN, The Netherlands, Aug. 20, 2004 (PRIMEZONE) -- Dutch biotechnology company Crucell N.V. (Euronext:CRXL) (Nasdaq:CRXL) and allied contract manufacturer DSM Biologics announced today that...